title: Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
abstract: OBJECTIVE
  The aim of these studies was to validate the analytical performance of a cell cycle progression (CCP) gene signature that provides prognostic information for early stage lung adenocarcinomas.
  
  
  METHODS
  Formalin-fixed paraffin-embedded (FFPE) lung resections were evaluated by quantitative RT-PCR for the expression of 31 target and 15 housekeeper genes comprising the CCP score.
  
  
  RESULTS
  The signature had a standard deviation (SD) of 0.06 score units and a dynamic range spanning CCP scores between -13 and 14. The average amplicon efficiencies for target and housekeeper genes were 107% and 105%, respectively. All but one amplicon had a SD <0.5 CT.
  
  
  CONCLUSIONS
  These studies demonstrate that the gene signature is robust and reproducible, making it suitable for use in a clinical setting.
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: M Bryan
authors.initials: MB
authors.lastname: Warf
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Placede G
authors.initials: PG
authors.lastname: Fosso
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Elisha
authors.initials: E
authors.lastname: Hughes
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Perry
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Krystal L
authors.initials: KL
authors.lastname: Brown
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Julia E
authors.initials: JE
authors.lastname: Reid
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Kolquist
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Susanne
authors.initials: S
authors.lastname: Wagner
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Alexander
authors.initials: A
authors.lastname: Gutin
authors.affiliation: Myriad Genetic Laboratories Inc., 320 Wakara Way, Salt Lake City, UT 84108, USA.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Roa
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D014408:Biomarkers, Tumor / Q000235:genetics*; D002453:Cell Cycle / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics; D020869:Gene Expression Profiling; D052138:Genes, Neoplasm / Q000235:genetics*; D006801:Humans; D016014:Linear Models; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D020871:RNA Stability
chemical_list: D014408:Biomarkers, Tumor
keywords: FFPE; analytical validation; cell cycle progression; early-stage lung adenocarcinoma; gene expression; quantitative RT-PCR